



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/089,501	04/22/2002	Hiroyuki Saito	053-466-0325	9449
22428	7590	12/23/2008		
FOLEY AND LARDNER LLP			EXAMINER	
SUITE 500			BURKHART, MICHAEL D	
3000 K STREET NW			ART UNIT	
WASHINGTON, DC 20007			PAPER NUMBER	
			1633	
			MAIL DATE	
			DELIVERY MODE	
			12/23/2008	
			PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/089,501

Applicant(s)

SAITO ET AL.

Examiner

MICHAEL BURKHART

Art Unit

1633

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 01 December 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 45-49, 51-56 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 45-49, 52, 53 and 55 is/are rejected.
- 7) ☒ Claim(s) 51, 54 and 56 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/888)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114 was filed in this application after appeal to the Board of Patent Appeals and Interferences, but prior to a decision on the appeal. Since this application is eligible for continued examination under 37 CFR 1.114 and the fee set forth in 37 CFR 1.17(e) has been timely paid, the appeal has been withdrawn pursuant to 37 CFR 1.114 and prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 12/1/2008 has been entered.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 45-49, 52, 53 and 55 are rejected under 35 U.S.C. 102(e) as being anticipated by Wong et al (U.S. Patent 5,986,065, EFD 3/10/1997). **This rejection is maintained for reasons made of record in the Office Action dated 4/4/2008, and for reasons set forth below.**

Regarding claim 53, Fab and other fragments of the antibodies of Wong et al are disclosed in col. 9, lines 41-50. Regarding claim 55, because the antibodies of Wong et al have the same activity as the claimed antibodies, i.e. they bind human TF and inhibit the activation of Factor X by the TF/Factor VIIa complex, they are considered to bind the same "site" as the

instantly claimed antibody, i-b2. There is no limiting definition of the term "site" in the instant specification and thus it is given a reasonably broad interpretation to include portions of the human TF protein involved in Factor X activation.

Response to Arguments

Applicant's arguments filed 12/1/2008 have been fully considered but they are not persuasive. Applicants essentially assert that: 1) Wong fails to teach suppressing hypertrophy of the vascular intima (e.g. restenosis), rather, Wong is directed to treating short term active thrombosis; 2) the influence of anti-TF antibodies on the proliferation of intima tissue was not known prior to the instant invention.

Regarding 1), applicants confusingly equate "hypertrophy of the vascular intima" with restenosis, then appear to argue that restenosis is thrombosis, or undesirable blood clotting. The two are quite different as applicants point out. Restenosis, absent a definition in the specification, is loosely defined as reoccurrence of stenosis (a narrowing of a vessel) after corrective surgery or treatment. Wong et al clearly teach treating restenosis with anti-TF antibodies for reason made of record. This is all that is required to anticipate the instant claims, as restenosis is a prime example of "hypertrophy of the vascular intima", a term also not defined in the specification. "Hypertrophy" is loosely a growth of non-tumorous nature and "intima" is considered to be the innermost membrane of a vein, vessel, etc. Furthermore, since the antibodies of Wong et al have the same activity as those instantly claimed, they inherently have the same effect upon restenosis as the claimed antibodies.

Regarding 2), this is not required to anticipate the instant claims. Furthermore, the usefulness of anti-TF antibodies in treating restenosis following angioplasty was recognized in the prior art (US 6,287,794 , col. 3, lines 4-21).

Allowable Subject Matter

Claims 51, 54 and 56 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL BURKHART whose telephone number is (571)272-2915. The examiner can normally be reached on M-F 8AM-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Weitach can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael Burkhardt/
Primary Examiner, Art Unit 1633